Preferences of treatment strategies among women with low-risk dcis and oncologists

Grand Challenge Precision Consortium

Research output: Contribution to journalArticleAcademicpeer-review

10 Downloads (Pure)

Abstract

As ongoing trials study the safety of an active surveillance strategy for low-risk ductal carcinoma in situ (DCIS), there is a need to explain why particular choices regarding treatment strategies are made by eligible women as well as their oncologists, what factors enter the decision process, and how much each factor affects their choice. To measure preferences for treatment and surveillance strategies, women with newly-diagnosed, primary low-risk DCIS enrolled in the Dutch CONTROL DCIS Registration and LORD trial, and oncologists participating in the Dutch Health Professionals Study were invited to complete a discrete choice experiment (DCE). The relative importance of treatment strategy-related attributes (locoregional intervention, 10-year risk of ipsilateral invasive breast cancer (iIBC), and follow-up interval) were discerned using conditional logit models. A total of n = 172 patients and n = 30 oncologists completed the DCE. Patient respondents had very strong preferences for an active surveillance strategy with no surgery, irrespective of the 10-year risk of iIBC. Extensiveness of the locoregional treatment was consistently shown to be an important factor for patients and oncologists in deciding upon treatment strategies. Risk of iIBC was least important to patients and most important to oncologists. There was a stronger inclination toward a twice-yearly follow-up for both groups compared to annual follow-up.

Original languageEnglish
Article number3962
Number of pages14
JournalCancers
Volume13
Issue number16
DOIs
Publication statusPublished - 6 Aug 2021

Keywords

  • Active surveillance
  • De-escalating
  • Discrete choice experiment
  • Ductal carcinoma in situ
  • Patient preference

Fingerprint

Dive into the research topics of 'Preferences of treatment strategies among women with low-risk dcis and oncologists'. Together they form a unique fingerprint.

Cite this